Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1f83a84f-eb27-465c-811b-4de76fd8df13] => Array ( [runtime-id] => 1f83a84f-eb27-465c-811b-4de76fd8df13 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [e48528a9-a676-4c10-ab9f-83778f56c162] => Array ( [runtime-id] => e48528a9-a676-4c10-ab9f-83778f56c162 [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;e22c81faaba31f64080aee87a72bb64ddb8ad18d ) ) ) 1naresh2naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [1f83a84f-eb27-465c-811b-4de76fd8df13] => Array
        (
            [runtime-id] => 1f83a84f-eb27-465c-811b-4de76fd8df13
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [e48528a9-a676-4c10-ab9f-83778f56c162] => Array
                        (
                            [runtime-id] => e48528a9-a676-4c10-ab9f-83778f56c162
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;e22c81faaba31f64080aee87a72bb64ddb8ad18d
                )

        )

)

Table 2: Occurrence of adverse events following intrathecal MRI contrast agent administration^{^a}
Immediate Delayed (Days 1–3) 4 Weeks Late
Serious adverse events 
    Allergy reaction 1 (1%) 0 0 0
    Pulmonary embolism 0 1 (1%) 0 0
Nonserious adverse events 
    Headache 
        Mild 3 (3%) 1 (1%) 1 (1%)
        Moderate 13 (13%) 2 (2%) 0
        Severe 28 (28%) 1 (1%) 0
    Nausea 
        Mild 17 (17%) 0 0
        Moderate 5 (5%) 0 0
        Severe 34 (34%) 1 (1%) 0
    Dizziness 
        Mild 10 (10%) 0 1 (1%)
        Moderate 11 (11%) 1 (1%) 0
        Severe 17 (17%) 0 0
    Itch 3 (3%) 1 (1%) 0
    Warm feeling 7 (7%) 1 (1%) 0
    Paresthesia 12 (12%) 2 (2%) 0
    Vision problems 0 0 0
    Cognitive difficulties 0 0 0
    Discomfort at injection site and/or lumbar region 13 (13%) 2 (2%) 0
    Tremor 0 0 0
↵a Data are No. of individuals (percentage in parentheses).

	Immediate	Delayed (Days 1–3)	4 Weeks	Late
Serious adverse events
Allergy reaction	1 (1%)	0	0	0
Pulmonary embolism	0	1 (1%)	0	0
Nonserious adverse events
Headache
Mild		3 (3%)	1 (1%)	1 (1%)
Moderate		13 (13%)	2 (2%)	0
Severe		28 (28%)	1 (1%)	0
Nausea
Mild		17 (17%)	0	0
Moderate		5 (5%)	0	0
Severe		34 (34%)	1 (1%)	0
Dizziness
Mild		10 (10%)	0	1 (1%)
Moderate		11 (11%)	1 (1%)	0
Severe		17 (17%)	0	0
Itch		3 (3%)	1 (1%)	0
Warm feeling		7 (7%)	1 (1%)	0
Paresthesia		12 (12%)	2 (2%)	0
Vision problems		0	0	0
Cognitive difficulties		0	0	0
Discomfort at injection site and/or lumbar region		13 (13%)	2 (2%)	0
Tremor		0	0	0